Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailor-made versus routine treat-to-target management for newly diagnosed rheumatoid arthritis
ISRCTN16170070Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate, hydroxychloroquine, 5-aminosalicylic acid + sulphasalazine, filgotinib, methylprednisolone and 1 more in rheumatoid arthritis (RA) (2 arms), sponsored by Erasmus MC. Primary endpoint: Proportion of patients using a biologic or targeted synthetic DMARD after 10 months. Started Apr 2021; status: completed.
02
Drugs
methotrexatehydroxychloroquine5-aminosalicylic acid + sulphasalazinefilgotinibmethylprednisolone
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN16170070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16170070.